Boehringer Ingelheim USA Corporation

Nxera Pharma announced a focused restructuring plan targeting ≥JPY50 billion in net sales and ≥30% operating profit margin by 2030, with a 15% global workforce reduction affecting approximately 60 jobs.

Palatin Technologies reported significant progress on its melanocortin-based obesity programs, with oral small molecule PL7737 advancing toward IND submission and Phase 1 clinical trials in the first half of 2026.

Boehringer Ingelheim and CDR-Life announced a global licensing agreement worth up to $570 million to develop CDR111, a trispecific antibody-based T-cell engager designed to selectively target and deplete B cells for autoimmune disease treatment.

The Health Resources and Services Administration has approved eight pharmaceutical companies to participate in the 340B Rebate Model Pilot Program, which will begin on January 1, 2025.

Boehringer Ingelheim has acquired exclusive worldwide rights to a pre-clinical small molecule program from Kyowa Kirin targeting autoimmune diseases.

Boehringer Ingelheim has acquired a potentially first-in-class preclinical small molecule program from Accent Therapeutics targeting tumors with high interferon-stimulated gene (ISG) expression.

Enara Bio will present DARKFOX, a novel cancer-specific dark antigen derived from an alternative open reading frame of FOXM1, at the Society for Immunotherapy of Cancer meeting in November 2025.

Qurient has signed a licensing agreement with Synaffix to develop a dual-payload ADC combining Qurient's CDK7 inhibitor mocaciclib with Synaffix's exatecan-based technology.

TegMine Therapeutics has entered a strategic research collaboration with Boehringer Ingelheim to develop safer, more selective antibody-drug conjugates using TegMine's proprietary 2-Factor Antibody System.

Roche announced a definitive merger agreement to acquire 89bio for $14.50 per share in cash plus contingent value rights, totaling up to $3.5 billion.